A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Recruiting
Hoffmann-La Roche
Phase 2
2008-10-16
This is a global, multicenter, open-label safety extension study. Participants receiving
single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with
other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and
receiving benefit at the closure of parent study are eligible for continued treatment in this
study.
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Recruiting
Genentech, Inc.
Phase 2
2008-10-16
This is a global, multicenter, open-label safety extension study. Participants receiving
single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with
other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and
receiving benefit at the closure of parent study are eligible for continued treatment in this
study.
A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma
Completed
Genentech, Inc.
Phase 1
2012-08-13
This is an open-label, multicenter, Phase Ib, dose-escalation and cohort-expansion study of
atezolizumab (anti-programmed death-ligand 1 [PD-L1] antibody) in combination with
vemurafenib or vemurafenib plus cobimetinib in participants with BRAFV600-mutation positive
metastatic melanoma. Enrolled participants may continue treatment until they are no longer
experiencing clinical benefit as assessed by the investigator and in alignment with the
protocol.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
